Oruka Therapeutics Inc.
ORKA | NASDAQ
$96.02
-$0.85 (-0.88%)
Nov 2, 2026, 12:18 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|
Net Income | -105.43M | -83.72M | -9.93M | -19.32M | -9.74M |
Depreciation & Amortization | 83K | 27K | 114K | 91K | 93K |
Stock-Based Compensation | n/a | n/a | n/a | n/a | n/a |
Other Working Capital | -3.25M | 8.13M | -878K | 383K | 776K |
Other Non-Cash Items | 19.7M | 14.27M | 561K | 497K | 43K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | -2.56M | 11.59M | -1.66M | -28K | 1.88M |
Operating Cash Flow | -88.21M | -57.84M | -10.91M | -18.76M | -7.73M |
Capital Expenditures | -209K | -189K | -2K | -43K | -19K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -520.96M | -329.94M | n/a | n/a | n/a |
Sales Maturities Of Investments | 424.42M | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | -96.75M | -330.13M | -2K | -43K | -19K |
Debt Repayment | n/a | n/a | n/a | n/a | -408K |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | n/a | n/a | n/a |
Financial Cash Flow | 170.32M | 449.54M | n/a | 23.09M | 48.45M |
Net Cash Flow | -14.64M | 24.14M | -10.91M | 4.29M | 40.71M |
Free Cash Flow | -88.42M | -58.03M | -10.91M | -18.81M | -7.74M |
Adj. Free Cash Flow | -88.42M | -58.03M | -10.91M | -18.81M | -7.74M |
Maintenance CapEx | -83K | -27K | -2K | -43K | -19K |
Growth CapEx | -126K | -162K | n/a | n/a | n/a |
Owner Earnings | -88.29M | -57.86M | -10.91M | -18.81M | -7.74M |
Add to Watchlist
Select watchlists to add or remove ORKA